PSNL Earnings Date: Nov 3, 2026 (Estimated) — Personalis, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is PSNL's next earnings date?
Personalis, Inc. (PSNL) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.26 on revenue of $21.5M.
How did PSNL do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Personalis, Inc. posted EPS of -$0.30 versus the -$0.26 estimate, a miss of 15.4%. Revenue was $22.4M against a $17.1M estimate. The stock's 1-day post-earnings move was +0.0%.
How much does PSNL stock move after earnings?
PSNL beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.8% (up or down) in the day after earnings.
About Personalis, Inc.
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.26 | -0.30 | -15.38% | $22.4M | ❌ Miss | +0.00% | +3.70% | +23.74% |
| 2026-05-07 | Q1 2026 | -0.27 | -0.29 | -7.41% | $15.5M | ❌ Miss | -0.17% | +12.02% | +67.61% |
| 2026-02-26 | Q4 2025 | -0.29 | -0.26 | +10.34% | $17.3M | ✅ Beat | +0.33% | -5.20% | -29.79% |
| 2025-11-04 | Q3 2025 | -0.28 | -0.24 | +14.29% | $14.2M | ✅ Beat | -12.26% | -3.32% | +20.05% |
| 2025-08-05 | Q2 2025 | -0.25 | -0.23 | +8.00% | $17.2M | ✅ Beat | -21.90% | -18.97% | -9.75% |
| 2025-02-27 | Q4 2024 | -0.28 | -0.23 | +17.86% | $16.8M | ✅ Beat | -2.36% | -0.47% | -14.62% |
| 2024-11-06 | Q3 2024 | -0.35 | -0.64 | -82.86% | $25.7M | ❌ Miss | -22.58% | -14.87% | -25.63% |
| 2024-08-07 | Q2 2024 | -0.37 | -0.24 | +35.14% | $22.6M | ✅ Beat | +19.10% | +54.86% | +86.46% |
Showing last 8 quarters.